Advaxis

Advaxis, Inc. is a biotechnology company that uses a modified infectious microorganism to activate the immune system to treat cancer, infectious disease or allergic syndromes. Based upon over a 10 years of innovative work done by Yvonne Paterson, Ph.D., Professor of Microbiology at the University of Pennsylvania, it has been found that the unique microbe Listeria monocytogenes is capable of stimulating numerous aspects of the immune system simultaneously; coordinating innate, humoral (antibody), and cellular adaptive immune responses in an extremely effective response to existing cancers and other diseases. Unlike other therapeutic approaches, in pre-clinical research Advaxis’ Listeria technology has been able to consistently demonstrate complete therapeutic responses resulting in complete tumor regression.

Contact Details: The Technology Centre of New Jersey Suite 117 675 U.S. Route 1 North Brunswick 08902 United States of America Tel: 732-545-1590 Fax: 732-545-1084 Email: BD@advaxis.com WWW: www.advaxis.com/index.html

Recent Publications by Advaxis:
The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Invasive carcinoma of the cervix (ICC) is the second most common cancer in...	28th August, 2009	Advaxis Inc 675 US 1 North, North Brunswick, NJ 08902, USA.	Vaccine. 2009 Jun 19;27(30):3975-83. Epub 2009 May 3. DOI Direct Link
Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy. Listeria monocytogenes has been exploited previously as a vaccine vector...	31st January, 2009	Research and Development, Advaxis Inc., 675 US Highway One, Suite 120,	Clin Vaccine Immunol. 2009 Jan;16(1):96-103. Epub 2008 Nov 19. DOI Direct Link
Development of a Listeria monocytogenes based vaccine against prostate cancer. Prostate specific antigen (PSA) is a likely immunotherapeutic target...	21st August, 2008	Research and Development, Advaxis, Inc, North Brunswick, NJ, USA.	Cancer Immunol Immunother. 2008 Sep;57(9):1301-13. Epub 2008 Feb 14. DOI Direct Link

Press Releases on Advaxis:
Advaxis, Inc Initiation Coverage Review Issued By Scimitar Equity, LLC	15th July, 2008	Scimitar Equity, LLC	BOSTON, July 15 /PRNewswire/ --Scimitar Equity, LLC issues a review of Advaxis, Inc (OTC Bulletin Board: ADXS), entitled, "The New Generation of Cancer Immunotherapeutics". This
Novel cancer vaccine to be manufactured from live bacterium	1st July, 2003	Cobra Biomanufacturing	Novel cancer vaccine to be manufactured from live bacterium 29 July 2003. Cobra Biomanufacturing signs long-term supply agreement to manufacture active ingredient for Advaxis’

BioNews Results for Advaxis:
D.C. Vaccine Conference Attracts Government Policy Makers and Biotech Innovators	Yahoo! Canada:  Nov 9 2009 2:44PM Matching: advaxis
Study: Gene therapy can reduce symptoms of Huntington's disease	News-Medical.Net:  Oct 31 2009 6:02AM Matching: advaxis
Advaxis CEO Thomas A. Moore to Present at the 8th Annual BIO Investor Forum	Pharma Live:  Oct 30 2009 5:27AM Matching: advaxis
Medical News: Advaxis Receives IRB Approval For Cervical Dysplasia Trial Of ADXS11-001	Medical News Today:  Oct 30 2009 1:42AM Matching: advaxis
Updates for Arrayit (OTC:ARYC), Enzon (NASDAQ:ENZN), Advaxis (OTC:ADXS), BioSphere (NASDAQ:BSMD)	Los Angeles Chronicle:  Oct 30 2009 6:50PM Matching: advaxis
Promote your company here: BioNewsCast - Press Release Distribution	→View more Advaxis news.

Advaxis (ADXS.OB) Financial information Links from Barchart
ADXS.OB Quote from from Barchart.com
ADXS.OB Chart from from Barchart.com
ADXS.OB Profile from from Barchart.com
ADXS.OB Opinion from from Barchart.com
→View more Advaxis finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 1082 times since April 2007, the link to the organisation's website has been followed 200 times

Recent Search Terms used to find this page: LISTERIA MONOCYTOGENES VACCINATION 2009 | The first clinical use of a live-attenuated Listeria monocytogenes vaccine a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine. 2009 Jun 19 27 30 3975-83 | The first clinical use of a live-attenuated Listeria monocytogenes vaccine A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix | advaxis | advaxis | advaxis | advaxis.ob | Advaxis | advaxis | ADXS.OB | .

Search for more companies in North Brunswick

Search for more companies in

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Advaxis